Sergey Vlasenko is an associate vice president with Agilent, leading the company's pharma/biopharma efforts focusing on strategic, high-growth opportunities. Sergey joined Agilent in 2018 through the acquisition of ProZyme, where he was CEO. Sergey has a master's degree in chemistry and a Ph.D. in enzyme kinetics from Moscow State University. He has also completed the Hass School of Business executive development program.